ZEALAND PHARMA A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 767.5 DKK | +18.62% |
|
+15.85% | +105.65% |
| 06-21 | Zealand Pharma shares soar on obesity results | CF |
| 06-21 | Europe's STOXX 600 falls as tech, banks drag | RE |
Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity.
At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.
Calendar
2024-08-15
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
767.5
DKK
Average target price
806.6
DKK
Spread / Average Target
+5.09%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +105.65% | 6.85B | |
| +15.19% | 121B | |
| +19.91% | 114B | |
| +8.24% | 23.61B | |
| -19.80% | 20.43B | |
| -16.19% | 16.55B | |
| -13.45% | 16.45B | |
| -44.35% | 15.59B | |
| +2.13% | 13.54B | |
| +66.67% | 15.19B |
- Stock Market
- Equities
- ZEAL Stock
- News Zealand Pharma A/S
- Zealand Pharma, Boehringer Ingelheim Weight Loss Compound Hits Midstage Endpoints for Liver Fibrosis
